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Cytochrome cWhen cells kill themselves, they usually do so by activatingmechanisms that have evolved speciﬁcally for that
purpose. These mechanisms, which are broadly conserved throughout the metazoa, involve two processes:
activation in the cytosol of latent cysteine proteases (termed caspases), and disruption of mitochondrial
functions. These processes are linked in a number of different ways. While active caspases can cleave proteins
in the mitochondrial outer membrane, and cleave and thereby activate certain pro-apoptotic members of the
Bcl-2 family, proteins released from themitochondria can trigger caspase activation and antagonise IAP family
proteins. This reviewwill focus on the pro-apoptoticmolecules that are released from themitochondria of cells
endeavouring to kill themselves. This article is part of a Special Issue entitled Mitochondria: the deadly
organelle.ondria: the deadly organelle.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
When Kerr, Wyllie and Currie ﬁrst proposed the apoptosis concept
in 1972, they noted that in apoptosis, as opposed to necrosis, the
mitochondria did not appear abnormal until late in the process [1].
However, as study of physiological cell death progressed from the era
of morphology to the era of biochemistry and molecular biology, the
role of the mitochondria in cell death had to be reassessed.
The idea that mitochondria might play a key role in cell death
was ﬁrst raised by David Hockenbery, who was working with Stanley
Korsmeyer [2]. They were studying the localization of the cell death
inhibitor Bcl-2, the ﬁrst component of the cell death mechanism
to be recognised [3,4]. Although earlier analysis by Cleary et al. had
shown that Bcl-2 associates with intracellular membranes via its
hydrophobic carboxy-terminus, with the main body of the protein in
the cytosol [5,6], Hockenbery et al. concluded that Bcl-2 was an
integral protein of the innermitochondrial membrane [2]. Subsequent
work has vindicated Cleary's initial ﬁndings [7], and shown that the
fraction of Bcl-2 that associates with mitochondria is bound to the
outer, rather than the inner membrane. Nevertheless, their paper
drew cell death researchers’ attention to the mitochondria for the ﬁrst
time.
In an effort to determine what mitochondrial function might be
required for apoptosis, Jacobson et al. transfected Bcl-2 into normal
cells, and those lacking mitochondrial DNA, and whose mitochondrialwere therefore incapable of generating energy by oxidative phos-
phorylation [8]. Because Bcl-2 was able to inhibit death of both
types of cells, as well as rho zero cells cultured in anoxic conditions,
they concluded that neither apoptosis nor Bcl-2's protective function
required mitochondrial respiration.
In 1994, Newmeyer et al., who were studying apoptosis in a cell-
free system derived from Xenopus oocytes, found that a mitochondrial
factor was necessary for activation of the endonuclease that cleaves
nuclear DNA during apoptosis [9]. Furthermore, as release of this
factor could be prevented by Bcl-2, their results suggested Bcl-2 acted
somewhere upstream of the mitochondria, and the mitochondrial
factor(s) were needed for activation of the endonucleases responsible
for the DNA “ladders” used as a marker of apoptosis.
Soon after, Kroemer's group reported that when lymphocytes
were given an apoptotic stimulus, they lost the electrical potential
across the inner mitochondrial membrane, and this occurred prior to
cleavage of the genomic DNA [10].
Like Newmeyer, Wang's group were using cell free systems to look
for molecules that could activate the apoptotic endonucleases. They
found that cytochrome c (cyt c), which in healthy cells resides in the
mitochondrial inter-membrane space, was, following an apoptotic
stimulus, released into the cytosol where it triggered activation of the
endonucleases [11]. Their subsequent work elucidated the biochem-
ical details of the pathway. They revealed that Bcl-2 could prevent loss
of cyt c from the mitochondria, but once in the cytosol, cyt c bound to
the adaptor protein Apaf-1. This caused activation of caspase 9 and
caspase 3, which cleaved the endonuclease inhibitor ICAD, thus
freeing CAD (Caspase-Activated DNAse), which cleaved the genomic
DNA [12–15].
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2.1. Cytochrome c
In healthy cells, cyt c exists in the mitochondrial inter-membrane
space where it acts in the electron transport chain to transfer elec-
trons from complex III to complex IV. In the cytoplasm of cells under-
going apoptosis, cyt c binds to Apaf-1, which binds to caspase 9, thus
forming the apoptosome [16,17]. Each cytochrome c polypeptide
binds a haem molecule, which is necessary for it to carry electrons,
and is also required for cyt c to activate Apaf-1 [12,18].
By binding to Apaf-1 and triggering formation of the apoptosome,
presence of cyt c in the cytosol is sufﬁcient to cause caspase-dependent
cell death, but is it necessary for cells to die by themechanism that bcl-
2 can block? Two sets of experiments suggest that this is not the case,
and suggest that cell death occurs evenwhen cyt c cannot bind Apaf-1.
They show that although cyt c and Apaf-1 are potent caspase acti-
vators, and can efﬁciently cause cell death, neither are essential for
cell death by the mechanism Bcl-2 can block.
Firstly, cells cultured in anoxic conditions cannot synthesize haem,
and hence only contain apo-cytochrome c [19]. Nevertheless, such
cells are still killed by an apoptotic stimulus such as staurosporin, and
cell death is still inhibited by Bcl-2 [8]. Presumably, something other
than Apaf-1 activated caspases killed the cells. The cells also did not
die due to lack of mitochondrial respiration, because these cells were
producing ATP by anaerobic glycolysis.
Secondly, genetic experiments in which the genes for Apaf-1 were
deleted, or the genes for cyt cwere modiﬁed so that it could no longer
bind to Apaf-1 but could still function in mitochondrial respiration,
showed that although cell death is somewhat delayed, it still occurs
both in vitro and in vivowhen Apaf-1 cannot be activated, or is absent
[20–24].
These experiments suggest that although cyt c is a molecule that is
released from the mitochondria during apoptosis, and can accelerate
cell death by binding to Apaf-1 and activating caspases, cyt c does not
play an essential role in cell death, because cell death occurs normally
in mice (of the right genetic background) that lack Apaf-1 or bear a
form of cyt c that cannot bind to Apaf-1.
2.2. Smac/Diablo
Smac (second mitochondrial activator of caspases)/Diablo (direct
IAP binding protein with low pI) was given its alternative names
because of the methods used to identify it. Wang's group isolated
Smac/Diablo from HeLa cell lysates as a component from solubilized
membranes that could enhance activation of caspase 3 in vitro, and
found that, like cyt c, Smac was a mitochondrial protein released into
the cytosol in cells undergoing apoptosis [25]. Vaux's group isolated
Smac/Diablo as a protein that could be co-immunoprecipitated from
cell lysates together with XIAP [26].
By binding, via its N-terminal IAP Binding Motif (IBM), to the
baculoviral IAP repeats (BIRs) of XIAP, cytosolic Smac/Diablo was able
to displace processed caspase 9 and caspase 3, whichwere then free to
dismantle the cell [27–29]. Indeed, even short peptides corresponding
to the IBM were able to promote apoptosis of some tumor lines [30].
Observations such as these prompted pharmaceutical companies to
develop synthetic Smac mimetic compounds, to see whether antag-
onism of IAPs in vivo could cause tumor cell death. Although these IAP
antagonist compounds can indeed kill certain cancer cell lines, and
several have entered clinical trials, questions remain about the
functions of, and requirements for, Smac/Diablo in both healthy
cells and those undergoing apoptosis.
For example, gene knockout experiments in mice have not given
much support to the notion that Smac/Diablo plays import roles
either in healthy cells or cells undergoing apoptosis. Mice lacking
Smac/Diablo developed normally, and were fertile. Moreover, noabnormality could be detected in any cell type, no matter what
stimulus was used [31]. Similarly, mice mutant for XIAP showed no
overt phenotype, and exhibited no change in sensitivity to apoptotic
stimuli [32]. The simplest explanation for failure to detect a
phenotype in these mice is that both Smac/Diablo and XIAP are
redundant, presumably with other IAP binding proteins, and other
IAPs, respectively. What are the other IAP binding proteins?2.3. HtrA2/Omi
The co-immunoprecipitation experiments that allowed identiﬁca-
tion of Smac/Diablo as an XIAP binding protein also identiﬁed other
proteins [26,33,34]. In each case, the IAP-binding proteins were
mitochondrial proteins, and all bore an IBM that allowed them to bind
to the BIRs of IAPs. One of them, HtrA2/Omi, was also identiﬁed by
other groups by virtue of its ability to bind to IAPs [35–37].
In the mitochondrial intermembrane space, HtrA2/Omi acts as a
chaperone and serine protease that re-folds or degrades misfolded
mitochondrial proteins, much like its bacterial homolog, HtrA, does
in Escherichia coli [38]. Bacterial HtrA (also known as DegP) forms a
hexameric complex [39] that functions in a way reminiscent of the
proteasome in eukaryotic cells.
Deletion of the genes for HtrA2/Omi in mice did not cause
resistance to cell death, but resulted in development of a neurode-
generative disease that caused death by 30 days. This was presumably
due to accumulation of misfolded proteins in the mitochondria of
long-lived neuronal cells [40]. Furthermore, mice with deletion
of both Smac/Diablo as well as HtrA2/Omi genes had the same
phenotype as those lacking just HtrA2/Omi, providing no support for
the hypothesis that Smac/Diablo and HtrA2/Omi have redundant
functions [40].
Over-expression of HtrA2/Omi does have some pro-apoptotic
activity, such as the ability to increase the amount of UV induced
apoptosis of a cell line transfected with XIAP, but it was weaker
than Smac/Diablo, and it was still able to do so, albeit to a reduced
extent, even if its IBM was mutated. Together with the results of
the genetic experiments [40,41], these results raise the possibility
that increased sensitivity to apoptosis caused by over-expression
of HtrA2/Omi is due to presence of a serine protease in the cyto-
plasm, rather than HtrA2/Omi having a physiological role as an IAP
regulator [33,36,37].2.4. Other mitochondrial IAP binding proteins (Nipsnap3 & 4, glutamate
dehydrogenase, ClpX, LRPPR, 3-hydroxyisobutyrate dehydrogenase)
In addition to Smac/Diablo and HtrA2/Omi, Verhagen et al. have
identiﬁed six further proteins that normally reside in the mitochon-
dria, but bear IBMs and are capable of binding to IAPs if released into
the cytosol [34]. Although it is possible that they can antagonize
IAPs, and do so in Smac/Diablo and HtrA2/Omi mutant cells, thereby
allowing them to undergo apoptosis, this seems unlikely. Most of
these proteins have some other, well established role in the mito-
chondria, and none show signiﬁcant pro-apoptotic activity when
expressed in the cytoplasm. An alternative possibility is that in mam-
malian cells there are IBM binding proteins that are produced and
reside in the cytosol, just as the IAP antagonists Reaper, Grim, HID and
Sickle do in insect cells [42,43].3. Other apoptogenic proteins released from mitochondria
There is evidence that a number of other pro-apoptotic proteins
are released from the mitochondria, but in general the evidence is
weak and inconsistent.
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AIF was initially thought to be a mitochondrial cysteine protease
whose release could be blocked by Bcl-2, but following an apoptotic
stimulus translocated from the mitochondria to the nucleus to cause
DNA fragmentation and cell death [44]. Moreover, it was claimed that
AIF was essential for programmed cell death [45], and that in the
nucleus it directly bound to DNA [46]. However, more recent genetic
and biochemical evidence has shown that AIF is not required for cell
death [47], but is a highly conserved oxidoreductase/NADH oxidase
that is a component of complex I of the mitochondrial electron
transport chain [48,49]. Furthermore, the phenotype of Harlequin
mice, which have low levels of AIF, resembles that of mice with
deﬁciencies of complex I [50,51], rather than those with excess cells,
which would have been expected if it had a pro-apoptotic function.
3.2. EndoG
By creating transgenic mice that ubiquitously expressed an
uncleavable form of ICAD {the Inhibitor of Caspase Activated DNAse
(CAD)}, Nagata's group showed that in the absence of CAD activity,
DNAse II from cells that engulfed the apoptotic corpses degraded
their DNA [52]. While trying to address the same question, Wang's
group used a biochemical approach, and identiﬁed the mitochondrial
endonuclease, endonuclease G (endoG) [53]. They found that endoG
was released from the mitochondria during apoptosis, and could
enter the nucleus and cleave genomic DNAwithout being activated by
caspases. Although analysis of an endoG knockout mouse initially
gave support to this model because cells from these mice were
resistant to certain apoptotic stimuli and exhibited reduced DNA
cleavage [54], when another group deleted the genes for endoG, but
did not also disrupt an adjoining gene, they found no phenotype [55].
Therefore it seems most likely that DNAse II is responsible for DNA
cleave when CAD cannot be activated, and even if endoG (and AIF) are
released from the mitochondria during apoptosis, they do not cause
DNA fragmentation, and the physiological signiﬁcance of their release,
if any, has yet to be established.
3.3. Caspases
There have been a number of reports that caspases, including
procaspases 2, 3, 8 and 9 reside in the intermembrane space of mito-
chondria in healthy cells, and are activated and released during
apoptosis [56–62]. However, these claims have not been conﬁrmed,
caspases do not appear in comprehensive mitochondrial proteome
analyses [63], and a mechanism by which caspase precursors could
enter the mitochondria in the absence of targeting sequences has not
been elucidated.
3.4. Others
Adenylate kinase 2 (AK2) is a protein that resides in the mito-
chondrial intermembrane space and can convert AMP, ADP and ATP
from one to another [64]. It has been reported that when released into
the cytosol, AK2 can bind to FADD and promote activation of caspase
10, but curiously, not caspase 8 [65]. However, mutation of AK2 genes
in humans leads to a degenerative disease termed reticular dysgenesis
that is consistent with deteriorating mitochondrial function, rather
than increased cell survival that would be expected if it had a pro-
apoptotic function [66,67].
4. How are mitochondrial proteins released?
Several models have been proposed to explain how proteins are
released from the mitochondria during apoptosis. For example, it has
been suggested that proteins are released via the permeabilitytransition pore, consisting of ANT, cyclophilin D and VDAC. While
this pore is usually too small to allow transit of proteins as large as
cytochrome c, it has been proposed that pores might fuse, or enlarge
in the presence of other proteins. Another model is that entry of ions
and water into the matrix causes the inner membrane to swell by
osmosis, causing the outer membrane to physically rupture [68,69].
Neither of these models are supported by analysis of cells from Bax:
Bak double deleted mice.
Currently the most widely favored model is that in the presence
of high levels of pro-apoptotic BH3-only Bcl-2 family members, or low
levels of anti-apoptotic Bcl-2 familymembers, Bak or Baxmultimerize to
form a pore in the outermitochondrial membrane [70]. Study of release
of tagged proteins from themitochondria during apoptosis suggest that
most are released via the same mitochondrial pore, and by a caspase
independentmechanism [71]. However, late in apoptosis, after caspases
become active in the cytosol, they can cleave proteins in the mito-
chondrial outer membrane, causing it to completely break down [72].
No matter what the mechanism by which mitochondrial proteins
exit the mitochondria, it is clear that in apoptosis proteins do leave,
but debate remains about the signiﬁcance of this occurrence.
5. (Lack of a) role in apoptosis of proteins released from the
mitochondria of invertebrate cells
Invertebrate model organisms such as Drosophila and Caenorhab-
ditis elegans have accelerated elucidation of many biological process-
es, not the least of which are the physiological mechanisms for cell
death. For example, genetic analysis of cell death during development
of C. elegans revealed that the caspase CED-3 is essential for pro-
grammed cell death in the worm, and it is activated by an Apaf-1 like
adaptor protein, CED-4. Moreover, the Bcl-2-like protein CED-9 is able
to prevent CED-4 from activating CED-3. However, in the worm CED-9
binds directly to CED-4 to inhibit it, rather than acting to prevent
release of proteins frommitochondria, as Bcl-2 does, by inhibiting Bax
and Bak in mammalian cells. Unlike Apaf-1, which hasWD40 domains
that can be bound by cytochrome-c, C. elegans CED-4 lacks WD40
domains, and appears to activate spontaneously when inhibition by
CED-9 is removed. Thus, although CED-9 and CED-4 can localize to
outer mitochondrial membranes, implementation of the apoptotic
process does not require any mitochondrial protein in the worm [73].
Drosophila also bears genes for homologs of Bcl-2, Apaf-1 and
caspases, and, like their C. elegans homologs, they are essential
for normal developmental cell death [74]. Although there were some
early reports that insect cytochrome c released from themitochondria
was needed to activate the Apaf-1 homolog dARK [75,76], more
thorough genetic and biochemical analysis indicates that dARK can
activate the caspase DRONC in the absence of cyt c, and Drosophila cyt
c does not bind to dARK, even though it has WD40 domains [77,78].
Study of cell death in insects revealed the roles of the IAPs and their
antagonists Reaper, HID, Grim and Sickle [79–81]. The IAPs were ﬁrst
identiﬁed in baculoviruses, which use them to prevent defensive
apoptosis of the host cell, allowingmore time for viral replication [82].
Based on their similarity to baculoviral IAPs, their cellular homologs
DIAP1 and DIAP2 were identiﬁed in the ﬂy [83,84]. Abrams screened
for ﬂies with abnormal cell death during development identiﬁed a
region (H99) required for developmental cell death [79]. Subsequent
work revealed that the pro-apoptotic proteins Reaper, HID, Grim and
Sickle bind directly to the IAPs via their amino-termini, which
resemble those of Smac/Diablo and HtrA2/Omi [85,86]. However,
unlike themitochondrial IAP antagonists, those fromDrosophila reside
in the cytosol, and are therefore not released from the mitochondria.
6. Conclusions
Although it is clear that Bax and Bak are critical mediators of
apoptosis that function at the mitochondria, the only mitochondrial
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mitochondria and plays a role in promoting cell death is cytochrome c.
It is clear that many other proteins are released at the same time, and
presumably via the same route as cyt c, but evidence is lacking that
any of them play essential roles in cell death, or that prevention of
their release will stop any cell from dying. Furthermore, as caspases
become active, they can cleave proteins of the outer mitochondrial
membrane, leading to secondary release of mitochondrial proteins
into the cytosol, but this is presumably a late, post-mortem event from
which a cell cannot recover.
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